1992•PubMedRequires access
[Co-operative on salvage chemotherapy with VP-16 for malignant lymphoma. Hanshin Study Group on Treatment for Hematological Disorders].
E Miyazaki, Yuuji Takemoto, A Kanamaru, Eizo Kakishita, K Nagai, T Masaoka, Hirotoshi Shibata, A Horiuti, Kazuo Tsubaki, T Yonezawa
Open publisher page 0 citations
Abstract
Forty one patients with refractory malignant lymphoma were treated with a combination of VP-16, ACM, BH-AC, MTX and PDN as a salvage chemotherapy. These patients were either resistant to frontline therapy or refractory in their relapses. Three patients (7%) achieved a complete remission and 14 patients (34%) attained a partial remission. An overall response rate was 41%. Major toxicities were myelosuppression, nausea, and vomiting. However, they were well tolerated. This regimen has been effective in the treatment for the patients with refractory malignant lymphoma.